NYSE · AMPFinancialsSecurities & Investments

Ameriprise Financial financials

$497.32+0.23%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Q2 '25
Jun 30
Q1 '25
Mar 31
Q4 '24
Dec 31
Q3 '24
Sep 30
Q2 '24
Jun 30
Q1 '24
Mar 31
Q4 '23
Dec 31
Q3 '23
Sep 30
Revenue$5.01B$4.89B$5.05B$4.89B$4.49B$4.48B$4.65B$4.56B$4.39B$4.33B$4.17B$4.08B
Gross profit$4.72B$4.57B$4.72B$4.55B$4.23B$4.10B$4.41B$4.13B$4.06B$4.03B$4.07B$3.74B
Gross margin94.1%93.5%93.6%93.0%94.3%91.5%94.8%90.6%92.5%93.2%97.6%91.7%
Operating income$1.37B$1.68B$1.46B$1.38B$1.53B$1.38B$1.57B$873.0M$1.41B$1.46B$754.0M$1.35B
Net income$1.11B$915.0M$1.01B$912.0M$1.06B$583.0M$1.07B$511.0M$829.0M$990.0M$377.0M$872.0M
Net margin22.2%18.7%20.0%18.6%23.6%13.0%23.0%11.2%18.9%22.9%9.0%21.4%
Diluted EPS$11.98$9.68$10.48$9.33$10.73$5.83$10.56$5.00$8.02$9.46$3.57$8.14
EBITDA$1.37B$1.67B$1.44B$1.36B$1.51B$1.35B$1.53B$837.0M$1.36B$1.42B$754.0M$1.31B
Operating cash flow$2.89B$459.0M$2.67B$2.20B$1.76B$1.69B$383.0M$3.05B$1.72B$1.44B$2.14B$925.0M
Free cash flow$2.85B$430.0M$2.63B$2.16B$1.73B$1.65B$325.0M$3.00B$1.70B$1.39B$2.09B$875.0M
Diluted shares92.9M94.5M96.2M97.8M98.8M100.0M101.4M102.2M103.4M104.6M105.7M107.1M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$10.25B$8.47B$10.10B$9.76B$8.38B$7.97B
Short-term investments$81.90B$77.39B$81.10B$81.87B$80.08B$76.88B
Total debt$6.53B$5.81B$5.86B$5.88B$6.01B$6.18B
Total assets$197.87B$184.45B$190.90B$190.09B$184.90B$179.06B
Total liabilities$191.50B$178.24B$184.35B$183.63B$178.82B$173.63B
Shareholders' equity$6.37B$6.21B$6.55B$6.46B$6.08B$5.43B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology